ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

AVTX Avalo Therapeutics Inc

16.6898
0.6898 (4.31%)
最終更新日: 23:19:28
15分遅延
名称 銘柄コード 市場 種別
Avalo Therapeutics Inc AVTX NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.6898 4.31% 16.6898 23:19:28
始値 安値 高値 終値 前日終値
16.20 16.146 17.42 16.00
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/0220:00GLOBEAvalo Therapeutics Appoints Biotech Leaders to Board of..
2024/3/3005:01GLOBEAvalo Reports 2023 Financial Results and Provides Business..
2024/3/2805:01GLOBEAvalo Acquires Anti-IL-1β mAb and Announces Private..
2024/2/1511:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1500:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0106:01EDGAR2Form 8-K - Current report
2023/12/2907:05EDGAR2Form 8-K - Current report
2023/12/2721:00GLOBEAvalo Therapeutics Announces 1-for-240 Reverse Stock Split
2023/12/2206:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2206:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2106:01EDGAR2Form 8-K - Current report
2023/12/0721:02EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/12/0721:01EDGAR2Form 8-K - Current report
2023/12/0721:00GLOBEAvalo Encourages Stockholders to Vote FOR the Reverse Stock..
2023/11/1621:15EDGAR2Form 8-K - Current report
2023/11/0921:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0921:04EDGAR2Form 8-K - Current report
2023/11/0921:00GLOBEAvalo Reports Third Quarter 2023 Financial Results and..
2023/10/3120:21EDGAR2Form 8-K - Current report
2023/10/3120:00GLOBEAvalo Completes Divestiture of AVTX-800 Series
2023/10/2005:15EDGAR2Form ARS - Annual Report to Security Holders
2023/10/2005:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/2005:01EDGAR2Form DEF 14A - Other definitive proxy statements
2023/10/1805:02EDGAR2Form 8-K - Current report
2023/10/0605:02EDGAR2Form PRE 14A - Other preliminary proxy statements
2023/9/2620:04EDGAR2Form 8-K - Current report
2023/9/2620:00GLOBEAvalo Therapeutics Successfully Eliminates $35 Million Debt..
2023/9/1405:03EDGAR2Form 8-K - Current report
2023/9/1322:12EDGAR2Form 8-K - Current report
2023/9/1220:10EDGAR2Form 8-K - Current report
2023/9/1220:00GLOBEAvalo Enters into Agreement to Divest AVTX-800 Series
2023/9/1120:22EDGAR2Form 8-K - Current report
2023/9/0620:00GLOBEAvalo to Present at the H.C. Wainwright 25th Annual Global..
2023/8/1505:23EDGAR2Form 8-K - Current report
2023/8/0905:11EDGAR2Form 8-K - Current report
2023/8/0806:27EDGAR2Form 8-K - Current report
2023/8/0806:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2023/8/0320:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0320:01EDGAR2Form 8-K - Current report
2023/8/0320:00GLOBEAvalo Reports Second Quarter 2023 Financial Results and..
2023/7/2121:25EDGAR2Form 8-K - Current report
2023/7/0705:01GLOBEAvalo to Participate in SVB Securities Therapeutics Forum
2023/6/2921:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2023/6/2907:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/6/2620:00GLOBEAvalo Announces Topline Data from Phase 2 PEAK Trial for..
2023/6/0120:00GLOBEAvalo to Present at the Jefferies Healthcare Conference
2023/5/2220:00GLOBEAvalo Announces Appointment of Michael Croft, Ph.D. and Jeff..
2023/5/1520:00GLOBEAvalo to Present at ATS 2023 Respiratory Innovation Summit
2023/5/1020:00GLOBEAvalo to Present at the 2023 RBC Capital Markets Global..
2023/5/0505:01GLOBEAvalo Reports First Quarter 2023 Financial Results and..

最近閲覧した銘柄

Delayed Upgrade Clock